CA2956960C - Oral composition for delivery of drugs and other substances - Google Patents

Oral composition for delivery of drugs and other substances Download PDF

Info

Publication number
CA2956960C
CA2956960C CA2956960A CA2956960A CA2956960C CA 2956960 C CA2956960 C CA 2956960C CA 2956960 A CA2956960 A CA 2956960A CA 2956960 A CA2956960 A CA 2956960A CA 2956960 C CA2956960 C CA 2956960C
Authority
CA
Canada
Prior art keywords
composition
general formula
carbon chain
agent
monoglyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2956960A
Other languages
English (en)
French (fr)
Other versions
CA2956960A1 (en
Inventor
Walter Shaw
Stephen W. Burgess
Shengrong LI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanti Polar Lipids LLC
Original Assignee
Avanti Polar Lipids LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanti Polar Lipids LLC filed Critical Avanti Polar Lipids LLC
Publication of CA2956960A1 publication Critical patent/CA2956960A1/en
Application granted granted Critical
Publication of CA2956960C publication Critical patent/CA2956960C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2956960A 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances Active CA2956960C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462035393P 2014-08-09 2014-08-09
US62/035,393 2014-08-09
PCT/US2015/044501 WO2016025401A1 (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances

Publications (2)

Publication Number Publication Date
CA2956960A1 CA2956960A1 (en) 2016-02-18
CA2956960C true CA2956960C (en) 2023-10-24

Family

ID=55304531

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2956960A Active CA2956960C (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances

Country Status (11)

Country Link
US (3) US9872908B2 (https=)
EP (1) EP3177279B1 (https=)
JP (1) JP6759203B2 (https=)
KR (2) KR102507657B1 (https=)
CN (1) CN107072967B (https=)
AU (1) AU2015301952B2 (https=)
CA (1) CA2956960C (https=)
DK (1) DK3177279T3 (https=)
ES (1) ES3033965T3 (https=)
IL (1) IL250394B (https=)
WO (1) WO2016025401A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3177279B1 (en) * 2014-08-09 2025-06-04 Avanti Polar Lipids, LLC Oral composition for delivery of drugs and other substances

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514755A1 (fr) 1981-10-21 1983-04-22 Rhone Poulenc Chim Base Procede de preparation de l'anhydride acetique
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
ZA831053B (en) * 1982-02-17 1985-03-27 Ciba Geigy Ag Lipids in aqueous phase
EP0102324A3 (de) * 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
IE59067B1 (en) * 1985-04-02 1993-12-15 Yesair David W Composition for delivery of orally administered drugs and other substances
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
JPH01274830A (ja) * 1988-04-28 1989-11-02 Asahi Denka Kogyo Kk 安全で且つ高度な界面活性を有する脂質組成物
JPH03127731A (ja) * 1989-10-12 1991-05-30 Yakult Honsha Co Ltd ビタミンｅの可溶化方法およびビタミンｅ製剤
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US20080152636A1 (en) * 2006-09-08 2008-06-26 Kaneka Corporation Composition containing reduced coenzyme Q10 and lysolecithin
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
EP3177279B1 (en) * 2014-08-09 2025-06-04 Avanti Polar Lipids, LLC Oral composition for delivery of drugs and other substances

Also Published As

Publication number Publication date
US10463738B2 (en) 2019-11-05
EP3177279A1 (en) 2017-06-14
CN107072967A (zh) 2017-08-18
JP6759203B2 (ja) 2020-09-23
US11510985B2 (en) 2022-11-29
US20180064813A1 (en) 2018-03-08
EP3177279A4 (en) 2018-04-18
DK3177279T3 (da) 2025-08-18
IL250394B (en) 2021-05-31
IL250394A0 (en) 2017-03-30
AU2015301952B2 (en) 2020-12-03
KR20220070551A (ko) 2022-05-31
KR20170033442A (ko) 2017-03-24
AU2015301952A1 (en) 2017-02-16
CN107072967B (zh) 2021-01-12
ES3033965T3 (en) 2025-08-11
US20200188518A1 (en) 2020-06-18
WO2016025401A1 (en) 2016-02-18
EP3177279B1 (en) 2025-06-04
JP2017524036A (ja) 2017-08-24
KR102507657B1 (ko) 2023-03-08
US20160166699A1 (en) 2016-06-16
CA2956960A1 (en) 2016-02-18
US9872908B2 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
ES2536177T3 (es) Formulaciones para la inyección de butanos catecólicos, incluyendo compuestos de NDGA, en animales
WO2012095543A1 (es) Nanocápsulas con cubierta polimérica
KR20120136415A (ko) 카르보스티릴 유도체, 및 실리콘 오일 및/또는 실리콘 오일 유도체를 함유하는 현탁액 및 케이크 조성물
WO2017002030A1 (en) Stable liquid formulations of melphalan
ES2946600T3 (es) Formulaciones líquidas de daptomicina
CA2956960C (en) Oral composition for delivery of drugs and other substances
US20200352870A1 (en) Compositions and related methods for targeted drug delivery
WO2017175098A1 (en) Stable liquid pharmaceutical formulations of bendamustine
JP5217136B2 (ja) 直腸、尿道および膣適用用半固形状製剤。
CN105504311B (zh) 一种壳聚糖衍生物水凝胶及其制备方法和应用
KR20090040299A (ko) 특별히 표적화된 국소 투여를 위한 주사용 약제학적 조성물
KR20170039347A (ko) 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
JP2008189626A (ja) 経口用グリチルリチン可溶化製剤及びその製造方法
CA3061480A1 (en) Formulation of nanostructured gels for increased agent loading and adhesion
KR20140043579A (ko) 무복계면 디클로페낙나트륨 및 그 제조방법
EP4559483A1 (en) Hyaluronic acid derivative drug composition and drug composition
CN101150956B (zh) 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方
TWI778069B (zh) 難水溶性成分經可溶化之微膠粒及含有該微膠粒之液劑
KR20140039663A (ko) 무복계면 멜록시캄 및 그 제조방법
JP2011074033A (ja) 外用医薬組成物
WO2020016474A1 (es) Nanosistemas con complejos
JPS59144715A (ja) 軟膏基剤
TR201820816A2 (tr) Si̇klodekstri̇n ve şeker i̇çeren stabi̇l enjekte edi̇lebi̇li̇r posakonazol formülasyonlari
KR20140043572A (ko) 무복계면 이트라코나졸 및 그 제조방법
TW201636005A (zh) 聚合物膠束載體組成物及聚合物膠束組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200810

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250826